BURLINGTON, N.C.--(BUSINESS WIRE)--Labcorp® (NYSE: LH), a leading global life sciences company, today announced a new collaboration with HealthVerity, Inc., the ...

NAMSA, a global leader in medical device testing, clinical research, and regulatory consulting, is pleased to announce it has ...

For the full fiscal year 2025, Wall Street analysts expect Labcorp’s diluted EPS to grow by 12% annually to $16.32, followed ...

The move adds Labcorp’s US biocompatibility, analytical testing, and preclinical research services to Namsa’s operations.

Already a monolith in the clinical testing space, Labcorp is aiming to further swell its testing capabilities with the acquisition of contract research organization Toxikon. The CRO provides ...

LabCorp reported net revenues of nearly $9.5 billion for 2016 through the contributions of 52,000 employees in approximately 60 countries. To learn more about LabCorp, visit www.labcorp.com, and to ...

The yet-to-be-named new company will be publicly traded. Separating the laboratory testing work of LabCorp from the clinical trial services business, much of which came from acquisitions, will enable ...

“Adding Toxikon underscores our commitment to nonclinical development and advances our capabilities for both drug development and medical device testing,” said Dr. Paul Kirchgraber, CEO of Labcorp ...

Laboratory Corporation of America Holdings LH or LabCorp recently partnered with Community Clinical Oncology Research Network, LLC (CCORN) to better understand the impact of disparities in precision ...

(Reuters) - Laboratory Corp of America Holdings missed estimates for quarterly profit on Tuesday, as its drug development unit struggled against curbs on animal imports, while a sharp fall in sales of ...

On July 28, 2022, Labcorp (NYSE: LH, $257.94; Market Capitalization: $23.3 billion), a leading global life sciences company, announced that its Board of Directors authorized a plan to spin-off ...